HPV DNA Detection via Mass Spectrometry Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting human papillomavirus (HPV) in biological samples are limited by non-specificity, requiring high molecule counts, and inability to identify specific HPV types, leading to false positives and impracticality in screening serum and blood for lower levels of HPV DNA.
Innovation Solution
The use of sensitive mass spectroscopy technology for the detection, identification, and quantification of HPV DNA down to single copy levels in biological samples, including mammalian bodily fluids, allowing for the determination of specific HPV types and their association with cancer or dysplasia, and the development of a two-stage screening method for enhanced sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If the Digene test is used for HPV detection, then HPV DNA can be detected in cervical samples, but the test cross-reacts non-specifically with HPV types other than known pathogenic types, causing false positives
Solution Approach 1:
The patent divides the HPV detection into two distinct stages: a screening stage using the Digene test to identify samples with HPV DNA, and a confirmation stage using mass spectrometry to specifically identify pathogenic HPV types. This segmentation allows the first test to cast a wide net while the second test provides precise identification, resolving the contradiction between detection capability and specificity.
Solution Approach 2:
The patent introduces mass spectrometry as an intermediary technology between the initial HPV DNA detection and the final diagnostic conclusion. This intermediary tool specifically identifies pathogenic HPV types by analyzing molecular weight characteristics, thereby filtering out false positives from non-pathogenic HPV types while maintaining the broad detection capability of the screening test.
2Quantity of substance
If the Digene test requires several thousand HPV molecules for positive reading, then detection sensitivity is improved, but screening of serum and blood becomes impractical where smaller numbers of molecules are present
Solution Approach 1:
The patent replaces the traditional mechanical/chemical detection methods (requiring thousands of molecules) with mass spectrometry, which can detect and quantify HPV DNA at the level of individual molecules. This substitution of detection mechanism enables the system to work effectively in serum and blood samples where HPV DNA is present at very low concentrations, making the system adaptable to multiple sample types.
Solution Approach 2:
The patent changes the detection parameter from absolute molecule count (thousands required for Digene test) to molecular weight-based identification through mass spectrometry. This parameter change allows the system to detect HPV DNA regardless of absolute concentration, enabling effective screening in serum and blood where the virus is present at trace levels.
3Quantity of substance
If the Digene test is used, then HPV DNA can be detected, but the test does not reveal which HPV type is found, leading to inability to distinguish pathogenic from non-pathogenic types
Solution Approach 1:
The patent implements a feedback mechanism where the mass spectrometry results provide specific information about HPV type back to the diagnostic process. This feedback loop allows the system to distinguish between pathogenic and non-pathogenic HPV types based on their molecular weight characteristics, thereby eliminating the information loss about HPV typing that occurs with the Digene test alone.
4Measurement precision
If mass spectroscopy technology is used for single copy level detection, then detection sensitivity is greatly improved, but the complexity of the detection system increases
Solution Approach 1:
The patent segments the detection system into two components: a simple, widely available screening test (Digene test) and a specialized confirmation tool (mass spectrometry). This segmentation allows the complex mass spectrometry to be used only when needed for confirmation, rather than requiring the entire system to be complex from the start, thereby managing overall system complexity while achieving high precision where required.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the detection of HPV in serum and blood at single copy levels, reducing false positives and providing accurate identification of HPV types associated with tumors, improving diagnostic capabilities for HPV-related cancers and dysplasias, and enabling monitoring of therapy.
Implementation Method 1
The invention comprises more sensitive mass spectroscopy technology that identifies individual HPV sequences, increases the sensitivity of detection of HPV DNA
Data Source
AI summary
The present invention comprises, without limitation, systems, methods, and compositions for the detection, identification, and quantification, down to the single copy level, of human papillomavirus (HPV) in biological samples, including but not limited to, mammalian body fluids and cervix scrapings, for purposes of detection, treatment and/or management of cancer and dysplasia.